NetraMark Holdings Inc. said it appointed Kevin Felix as a strategic advisor, bringing more than 25 years of experience in capital markets, asset management, corporate strategy and securities law to the clinical-intelligence firm.
Felix previously served as president of the Investment Office at Global Atlantic Financial Group, where he oversaw an approximately $175 billion investment portfolio. He also has held roles as president and chief executive of Scotia Capital (USA) Inc. and as global head of fixed income, currencies and commodities at Scotiabank, alongside independent directorships at several firms.
In his advisory capacity, Felix will focus on building relationships with institutional investors and investment-banking partners in Canada and the United States, advising on strategic transactions, corporate development and capital markets strategy. His educational background includes a master's degree in securities regulation from Georgetown University Law Center, a Juris Doctor from New York Law School and a bachelor of arts from Bucknell University.
CEO George Achilleos said the appointment coincides with NetraMark refining its commercialization strategy across the pharmaceutical sector. "As we advance commercialization and broaden the Company's relationships across the pharmaceutical and investment communities we are continuing to strengthen the level of experience around the organization," Achilleos said.
NetraMark describes itself as a clinical-intelligence company that applies artificial intelligence to pharmaceutical clinical trials. Its NetraAI product uses a topology-based algorithm to analyze patient data sets in clinical studies. The firm is listed on the Toronto Stock Exchange under TSX:AIAI, OTCQB under AINMF and Frankfurt under PF0.
